KOF, US1912411089

Barclays lifts Coca-Cola FEMSA stock target to USD 125

Published on 11/04/2026 at 14:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Coca-Cola FEMSA stock drew a higher Barclays price objective while its Equal Weight rating stayed unchanged. Revenue beat estimates, but EPS missed.

Analyst target meets mixed results

Barclays raised its price objective while retaining an Equal Weight view.
Coca-Cola FEMSA exceeded revenue expectations but missed the quarterly earnings consensus.
Analyst sentiment remains cautious despite the recent share-price advance.

KOF, US1912411089, Illustration mit AI erstellt.

Barclays raised its price target for Coca-Cola FEMSA on Tuesday, November 3, while keeping an Equal Weight rating on the bottler. MarketBeat reported that the brokerage lifted its objective from USD 122 to USD 125, pointing to a measured rather than bullish change in its assessment.

The company’s latest quarterly figures provide a mixed backdrop. Coca-Cola FEMSA reported quarterly earnings per share of USD 1.72, below the USD 1.89 consensus cited by MarketBeat. Revenue reached USD 4.41 billion and exceeded the USD 4.36 billion estimate.

Valuation keeps analysts cautious

MarketBeat said four analysts rate the stock Buy and six rate it Hold, producing a consensus Hold view and an average price target of USD 121.43. Other recent actions included a downgrade by Itau BBA to Market Perform with a USD 116 target, while JPMorgan raised its target to USD 127 and retained a Neutral rating.

The mixed analyst picture leaves the higher Barclays objective below some of the more constructive targets but above the latest consensus average cited in the report. For investors, the combination of revenue growth and an earnings miss keeps execution and margin development central to the valuation discussion.

Coca-Cola FEMSA stock traded at EUR 105.00 on Lang & Schwarz at 2:01 p.m. CET on Wednesday, November 4, 2026. Investors can follow the real-time quote of Coca-Cola FEMSA stock for the latest indication.